We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Takeda Pharmaceutical Co Ltd | LSE:0RN3 | London | Ordinary Share | JP3463000004 | TAKEDA PHARMACEUTICAL ORD SHS |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 49.35 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 4.05T | 317.02B | 200.3525 | 0.13 | 40.78B |
TIDM43CT TIDM0RN3
RNS Number : 7868M
Morgan Stanley
10 January 2019
AMMENT Section (2a) & (3a)
FORM 8.5 (EPT/NON-RI)
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)
Rule 8.5 of the Takeover Code (the "Code")
Hot Features
Premium
1. KEY INFORMATION
(a) Name of exempt principal trader: Morgan Stanley MUFG Securities Co., Ltd.
(b) Name of offeror/offeree in relation to whose relevant securities this Takeda Pharmaceutical Company Limited
form relates:
Use a separate form for each offeror/offeree
-----------------------------------------
(c) Name of the party to the offer with which exempt principal trader is Shire plc
connected:
-----------------------------------------
(d) Date position held/dealing undertaken 07 JANUARY 2019
For an opening position disclosure, state the latest practicable date
prior to the disclosure
-----------------------------------------
(e) In addition to the company in 1(b) above, is the exempt principal Yes - Shire plc
trader making disclosures
in respect of any other party to this offer?
If it is a cash offer or possible cash offer, state "N/A"
-----------------------------------------
2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER
If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.
(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
Class of relevant security: Ordinary
Interests Short positions
---------------- -----------------
Number % Number %
---------- ---- ----------- ----
(1) Relevant securities owned
and/or controlled: 4,496,087 0.57 35,613,485 4.54
---------- ---- ----------- ----
(2) Cash-settled derivatives: 34,789,824 4.44 3,559,859 0.45
---------- ---- ----------- ----
(3) Stock-settled derivatives
(including options) and agreements
to purchase/sell: 315,000 0.04 315,000 0.04
---------- ---- ----------- ----
TOTAL: 39,600,911 5.05 39,488,344 5.03
---------- ---- ----------- ----
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
(b) Rights to subscribe for new securities (including directors' and other employee options)
Class of relevant security in N/A
relation to which subscription
right exists:
Details, including nature of N/A
the rights concerned and relevant
percentages:
----
3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of Purchases/ Total number Highest price Lowest price
relevant sales of securities per unit paid/received per unit paid/received
security
Ordinary PURCHASES 2,050,765 4,082.0000 3,715.0000
JPY JPY
----------- --------------- ------------------------ ------------------------
Ordinary SALES 2,082,968 4,074.0000 3,715.0000
JPY JPY
----------- --------------- ------------------------ ------------------------
(b) Cash-settled derivative transactions
Class of Product description Nature of dealing Number of reference Price per
relevant e.g. CFD e.g. opening/closing securities unit
security a long/short position,
increasing/reducing
a long/short position
Ordinary CFD 3995.0000
LONG 9500 JPY
-------------------- ------------------------ -------------------- ----------
Ordinary CFD 4065.0000
SHORT 5100 JPY
-------------------- ------------------------ -------------------- ----------
Ordinary CFD 3995.0000
LONG 5100 JPY
-------------------- ------------------------ -------------------- ----------
Ordinary CFD 3970.9166
SHORT 1200 JPY
-------------------- ------------------------ -------------------- ----------
Ordinary CFD 4065.0000
SHORT 300 JPY
-------------------- ------------------------ -------------------- ----------
Ordinary CFD 3990.9130
LONG 100000 JPY
-------------------- ------------------------ -------------------- ----------
Ordinary CFD 4065.0000
SHORT 200 JPY
-------------------- ------------------------ -------------------- ----------
Ordinary CFD 4065.0000
SHORT 5100 JPY
-------------------- ------------------------ -------------------- ----------
Ordinary CFD 3995.0000
LONG 5100 JPY
-------------------- ------------------------ -------------------- ----------
Ordinary CFD 3995.0000
LONG 17900 JPY
-------------------- ------------------------ -------------------- ----------
Ordinary CFD 3983.6118
LONG 30400 JPY
-------------------- ------------------------ -------------------- ----------
Ordinary CFD 4037.3940
LONG 70800 JPY
-------------------- ------------------------ -------------------- ----------
Ordinary CFD 4010.0000
SHORT 1800 JPY
-------------------- ------------------------ -------------------- ----------
Ordinary CFD 3984.7945
LONG 7300 JPY
-------------------- ------------------------ -------------------- ----------
Ordinary CFD 3969.5000
LONG 1200 JPY
-------------------- ------------------------ -------------------- ----------
Ordinary CFD 3777.3750
SHORT 800 JPY
-------------------- ------------------------ -------------------- ----------
Ordinary CFD 3969.5000
LONG 11800 JPY
-------------------- ------------------------ -------------------- ----------
Ordinary CFD 3838.8642
SHORT 60697 JPY
-------------------- ------------------------ -------------------- ----------
Ordinary CFD 3715.0000
LONG 25000 JPY
-------------------- ------------------------ -------------------- ----------
Ordinary CFD 3995.0000
LONG 9500 JPY
-------------------- ------------------------ -------------------- ----------
Ordinary CFD 3981.9771
SHORT 129800 JPY
-------------------- ------------------------ -------------------- ----------
Ordinary CFD 3995.0000
SHORT 15428331 JPY
-------------------- ------------------------ -------------------- ----------
Ordinary CFD 3995.0000
LONG 15428331 JPY
-------------------- ------------------------ -------------------- ----------
Ordinary CFD 3995.0000
LONG 32700 JPY
-------------------- ------------------------ -------------------- ----------
Ordinary CFD 3995.0000
SHORT 32700 JPY
-------------------- ------------------------ -------------------- ----------
Ordinary CFD 3743.3446
SHORT 3263027 JPY
-------------------- ------------------------ -------------------- ----------
Ordinary CFD 3738.1715
LONG 3205527 JPY
-------------------- ------------------------ -------------------- ----------
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class Product Writing, Number Exercise Type Expiry Option
of description purchasing, of securities price e.g. American, date money paid/
relevant e.g. call selling, to which per unit European received
security option varying option etc. per unit
etc. relates
N/A N/A N/A N/A N/A N/A N/A N/A
------------- ------------- --------------- ---------- ---------------- ------- -------------
(ii) Exercise
Class of Product description Exercising/ Number of securities Exercise price
relevant e.g. call option exercised per unit
security against
N/A N/A N/A N/A N/A
-------------------- ------------ --------------------- ---------------
(d) Other dealings (including subscribing for new securities)
Class of relevant Nature of dealing Details Price per unit
security e.g. subscription, (if applicable)
conversion
N/A N/A N/A N/A
-------------------- -------- -----------------
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding,
formal or informal, relating to relevant securities which may be an inducement to deal
or refrain from dealing entered into by the exempt principal trader making the
disclosure and any party to the offer or any person acting in concert with a party to the
offer:
Irrevocable commitments and letters of intent should not be included. If there are no such
agreements, arrangements or understandings, state "none"
NONE
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between
the exempt principal trader making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which
any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
NONE
(c) Attachments
Is a Supplemental Form 8 (Open Positions) attached? YES
Date of disclosure: 10 JANUARY 2019
Contact name: Craig Horsley
------------------
Telephone number: +44(141) 245 7736
------------------
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.
The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.
SUPPLEMENTAL FORM 8 (OPEN POSITIONS)
DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING OPTION) POSITIONS,
AGREEMENTS TO PURCHASE OR SELL ETC.
Note 5(i) on Rule 8 of the Takeover Code (the "Code")
1. KEY INFORMATION
Full name of person making disclosure: Morgan Stanley MUFG Securities Co., Ltd.
Name of offeror/offeree in relation to whose relevant securities the Takeda Pharmaceutical Company Limited
disclosure relates:
-----------------------------------------
2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)
Class of Product Written Number of Exercise Type Expiry
relevant description or purchased securities price e.g. American, date
security e.g. call to which per unit European
option option or etc
derivative
relates
Ordinary PUT PURCHASED 125,000 4507.0000 European 13/12/2019
JPY
------------ ------------- ----------- --------- --------------- ----------
Ordinary CALL PURCHASED 125,000 4507.0000 European 13/12/2019
JPY
------------ ------------- ----------- --------- --------------- ----------
Ordinary PUT PURCHASED 60,000 4596.0000 European 14/06/2019
JPY
------------ ------------- ----------- --------- --------------- ----------
Ordinary CALL PURCHASED 60,000 4596.0000 European 14/06/2019
JPY
------------ ------------- ----------- --------- --------------- ----------
Ordinary PUT PURCHASED 65,000 4414.0000 European 14/06/2019
JPY
------------ ------------- ----------- --------- --------------- ----------
Ordinary CALL PURCHASED 65,000 4414.0000 European 14/06/2019
JPY
------------ ------------- ----------- --------- --------------- ----------
Ordinary PUT PURCHASED 65,000 4414.0000 European 13/12/2019
JPY
------------ ------------- ----------- --------- --------------- ----------
Ordinary CALL PURCHASED 65,000 4414.0000 European 13/12/2019
JPY
------------ ------------- ----------- --------- --------------- ----------
3. AGREEMENTS TO PURCHASE OR SELL ETC.
Full details should be given so that the nature of the interest
or position can be fully understood:
It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.
The currency of all prices and other monetary amounts should be stated.
The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
FEOEADFEFSANEFF
(END) Dow Jones Newswires
January 10, 2019 08:55 ET (13:55 GMT)
1 Year Takeda Pharmaceutical Chart |
1 Month Takeda Pharmaceutical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
